| Expression pattern: |
DN |
| Associated gene: |
MAT2A, TRIM25, AGO2 |
| Associated microRNA: |
- |
| Biological function: |
Inhibits cisplatin resistance and stemness by destabilizing MAT2A; increases cisplatin sensitivity; suppresses tumorigenicity and metastasis-related phenotypes under cisplatin treatment conditions. |
| Molecular mechanism: |
circARHGAP10 acts as an RNA scaffold to enhance TRIM25-MAT2A interaction, promoting K48-linked ubiquitination and ubiquitin-proteasome degradation of MAT2A; not a ceRNA/miRNA sponge. |
| Biological pathway or process: |
ubiquitination (promotes); ceRNA regulation (inhibits); chemoresistance (inhibits); stemness (inhibits); metastasis (inhibits) |
| Detected method: |
Q
S
|
| Validation methods: |
circRNA-seq; RNA-seq; RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; FISH / smFISH; RNA Pull-Down; RIP (RNA Immunoprecipitation); Co-IP; IF (Immunofluorescence); Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Colony Formation Assay; Transwell Assay; In Vivo Animal Model; IHC (Immunohistochemistry); H&E Staining; Survival Analysis; Clinical Sample Validation; Cohort Study; Bioinformatics Analysis |
| Clinical significance: |
Higher expression of circARHGAP10 was correlated with better prognosis, lower tumor burden with tumor grades, and lower recurrence rate; circARHGAP10 down-regulation associated with cisplatin-based chemotherapy. |
| Description: |
circARHGAP10 is down-regulated in bladder cancer and cisplatin-resistant BCa cells. It binds MAT2A and TRIM25 and functions as an RNA scaffold to enhance TRIM25-dependent (K48-linked) ubiquitination and proteasomal degradation of MAT2A, thereby suppressing methionine metabolism-associated stemness and reducing cisplatin resistance; higher circARHGAP10 predicts better prognosis and lower recurrence. |
| Confidence score: |
0.8961 |